Signaling of high mobility group box 1 (HMGB1) through toll-like receptor 4 in macrophages requires CD14.
about
Potential role of High mobility group box 1 in hepatocellular carcinomaDAMPs, MAMPs, and NAMPs in plant innate immunityIdentification of pharmacological modulators of HMGB1-induced inflammatory response by cell-based screeningLipopolysaccharide-induced NF-κB nuclear translocation is primarily dependent on MyD88, but TNFα expression requires TRIF and MyD88Neuropathic pain in rats with a partial sciatic nerve ligation is alleviated by intravenous injection of monoclonal antibody to high mobility group box-1Molecular mechanism and therapeutic modulation of high mobility group box 1 release and action: an updated review.The role of high mobility group box 1 in innate immunity.Toll-like receptor 4: innate immune regulator of neuroimmune and neuroendocrine interactions in stress and major depressive disorderLentivirus delivery of IL-10 to promote and sustain macrophage polarization towards an anti-inflammatory phenotype.HMGB1 in health and disease.Injury-induced MRP8/MRP14 stimulates IP-10/CXCL10 in monocytes/macrophagesToll-like receptor 4 (TLR4) antagonist eritoran tetrasodium attenuates liver ischemia and reperfusion injury through inhibition of high-mobility group box protein B1 (HMGB1) signaling.High systemic levels of the cytokine-inducing HMGB1 isoform secreted in severe macrophage activation syndrome.CD13 restricts TLR4 endocytic signal transduction in inflammation.Contributions of unique intracellular domains to switchlike biosensing by Toll-like receptor 4.Hypertension-Linked Pathophysiological Alterations in the Gut.High-mobility group protein box1 expression correlates with peritumoral macrophage infiltration and unfavorable prognosis in patients with hepatocellular carcinoma and cirrhosisHost gene expression analysis in Sri Lankan melioidosis patients.HMGB1 Inhibition During Zymosan-Induced Inflammation: The Potential Therapeutic Action of RiboflavinCharacterization of the Inflammatory Properties of Actively Released HMGB1 in Juvenile Idiopathic Arthritis.Peroxiredoxin 1 induces inflammatory cytokine response and predicts outcome of cardiogenic shock patients necessitating extracorporeal membrane oxygenation: an observational cohort study and translational approachHMGB1-Driven Inflammation and Intimal Hyperplasia After Arterial Injury Involves Cell-Specific Actions Mediated by TLR4.CD14 contributes to warm hepatic ischemia-reperfusion injury in micePrognostic value of HMGB1 in early breast cancer patients under neoadjuvant chemotherapy.The Role of HMGB1 in the Pathogenesis of Type 2 Diabetes.The HIV protease inhibitor saquinavir inhibits HMGB1 driven inflammation by targeting the interaction of cathepsin V with TLR4/MyD88Targeting the Receptor for Advanced Glycation Endproducts (RAGE): A Medicinal Chemistry Perspective.Mesenchymal-epithelial signalling in tumour microenvironment: role of high-mobility group Box 1.Innate immune mechanisms in transplant allograft vasculopathy.Stanniocalcin-1 attenuates ischemic cardiac injury and response of differentiating monocytes/macrophages to inflammatory stimuliToll-Like Receptors 2 and 4 Are Potential Therapeutic Targets in Peritoneal Dialysis-Associated Fibrosis.Lipopolysaccharide activates Toll-like receptor 4 (TLR4)-mediated NF-κB signaling pathway and proinflammatory response in human pericytesEthyl pyruvate pretreatment attenuates concanavalin a-induced autoimmune hepatitis in mice.Ulinastatin post-treatment attenuates lipopolysaccharide-induced acute lung injury in rats and human alveolar epithelial cellsDengue fatal cases present virus-specific HMGB1 response in peripheral organs.Inhibition of intimal hyperplasia in murine aortic allografts by administration of a small-molecule TLR4 inhibitor TAK-242.Inhibition of the cluster of differentiation 14 innate immunity pathway with IAXO-101 improves chronic microelectrode performance.Membrane Association Dictates Ligand Specificity for the Innate Immune Receptor NOD2.The innate immune response to ischemic injury: a multiscale modeling perspective.Radiotherapy-induced cell death activates paracrine HMGB1-TLR2 signaling and accelerates pancreatic carcinoma metastasis.
P2860
Q26864508-36D25525-2AA2-4F9A-BA28-858E50B42625Q28066924-CD7FBB64-7BA1-44F3-A056-72CB2793888AQ28533928-7AA7C6A7-2BB6-4C64-A99F-13F9B16BEA54Q29994846-D4E7D9D4-1D15-4A6E-A0A9-740676DA99FEQ31133799-1F92AA8D-B7ED-4A4C-8006-198CB290B2E2Q33751106-0F591A1B-F779-4DF0-BC97-237A06834FCDQ33941549-55F3BDFE-8D78-4188-A39C-28F558DB2D83Q34265484-F67F7AFD-99C5-4FE4-8425-1AFF10548BCFQ34512267-5665D975-E955-4D20-BCC7-5CE684391037Q34622835-DFB030FA-AF33-4DDD-A324-E625FBCB33D1Q34847755-29DC3967-3589-4F87-9DA2-C3FD73BFBF80Q35192812-F552167E-E9C8-4099-B5E4-5AB1ECB9512FQ35192858-C48E9F20-4BAF-41D1-944F-EF99726CBD05Q35472323-E4B02666-A2F2-41F4-A517-4F5F1D981A68Q35580757-7EB6BAB8-EAB1-48C1-BAC9-7658E1542884Q36178777-C7A2FB42-B83C-4F58-84B9-210F0B32FB62Q36190325-2F63A272-F8D0-43B0-8D07-ABE1652E79B7Q36409109-622EDB59-02EC-4444-81D0-B51A8F139C30Q36723856-BCA831D5-3C04-456F-8174-C3870B98BD7BQ36827894-94418DF9-3211-4D10-800B-6A04E8998619Q36865282-27D70469-2A2A-435E-831D-7D50B38BC4DBQ36935091-AC431AC0-C625-4C73-8418-E40AD46D01F4Q37034816-44A06C59-3818-40D4-ACE4-AF86FDD77CA8Q37321088-0B3AB4C0-DEB1-4A8B-9CE9-1732E5B28C71Q37560287-3EA2EF0C-393B-4801-8049-B677CD6BC822Q38357779-2AB9610D-7B7D-49ED-A4F2-39A68732951DQ38686477-26ECC1DA-6946-486F-BDFA-08A666D469C7Q38786090-57C7B4C2-6139-4622-8E9B-B0FDE11F384CQ38808100-B8B410C7-61E2-4993-B64E-72EDCE4A8283Q39549057-AAFFAAAE-AF98-48AF-B2F9-A9E640069561Q40608326-01D509EB-3328-4A24-BC71-CDE2BB7FB7DCQ41889316-8E9AB65E-4227-4678-8133-52B39F4989B5Q41909868-991E038D-A231-4FEC-B3BF-C29FB7D1773CQ42315219-1AA05774-4CA3-499F-9602-20AF1F0DD7D5Q45324373-C26FE6D3-0914-453A-9923-C9A59FFA1300Q45913402-A2310645-9B6B-4BC7-B830-2DBD4089C86CQ47270261-C327C7ED-65C0-425F-84FF-3AA3069E3C9EQ48124216-06A1B442-6121-4F11-AE74-A7AA56015943Q52327759-DF0148FB-ABD4-4FDF-99E6-CB2DAC3CC9B2Q52609417-FD32DBCC-4ED8-4850-AFCE-C9AE4FAA6725
P2860
Signaling of high mobility group box 1 (HMGB1) through toll-like receptor 4 in macrophages requires CD14.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Signaling of high mobility gro ...... in macrophages requires CD14.
@en
type
label
Signaling of high mobility gro ...... in macrophages requires CD14.
@en
prefLabel
Signaling of high mobility gro ...... in macrophages requires CD14.
@en
P2093
P2860
P1433
P1476
Signaling of high mobility gro ...... 4 in macrophages requires CD14
@en
P2093
John P Pribis
Melanie J Scott
Michael Lotze
Patricia Loughran
Richard Shapiro
Sun Young Kim
Timothy R Billiar
P2860
P2888
P356
10.2119/MOLMED.2012.00306
P407
P577
2013-05-20T00:00:00Z
P5875
P6179
1078705145